A reference for health system leaders on what each kind of evidence proves, and how published studies of Pulsenmore ES illustrate each one.

Health systems should look for six kinds of evidence before adopting remote prenatal monitoring, and the published studies of Pulsenmore ES, a physician-prescribed home prenatal ultrasound system with FDA De Novo marketing authorization, illustrate each. The six kinds are regulatory authorization, clinical performance, accuracy, safety and outcomes, patient experience and clinical implementation. Each addresses a different question, so strength in one area does not cover the others. Adoption also depends on clinical workflows, patient eligibility, timely interpretation and links to in-person care.
Beyond regulatory approval: evaluating clinical readiness
Introducing a medical device into prenatal care requires more than showing that it works. Healthcare leaders must evaluate whether it performs reliably, whether patients can use it successfully, whether its use is associated with acceptable clinical outcomes, and how it fits into existing care pathways.
1. Regulatory authorization and intended use
In November 2025, Pulsenmore received FDA De Novo marketing authorization for its home prenatal ultrasound system. The authorization covers use in singleton pregnancies between 14 and 38 weeks of gestation, including fetal heart rate determination by healthcare professionals from home-acquired ultrasound images. The system supports two approaches: app-guided scanning, performed independently by the patient and subsequently reviewed by a clinician, and clinician-guided scanning, performed with real-time professional guidance. For healthcare organizations, the key consideration is whether the authorized indications align with the intended patient population, clinical objectives and care delivery model.
2. Clinical performance in patients’ hands
Early research in Israel involving 100 pregnant women demonstrated the feasibility of patient-operated ultrasound, with fetal cardiac activity detected in 95.3 percent of scans. More recently, the multicenter U.S. HOLA study evaluated 162 women across four clinical institutions, generating 1,370 ultrasound scans. The study reported successful fetal cardiac activity assessment in 99.2 percent of clinician-guided scans and 96.5 percent of app-guided scans.
3. Accuracy and clinical reliability
Research at Rabin Medical Center evaluated remote fetal heart rate measurements against conventional ultrasound examinations. Additional studies in Israel and the United States investigated the feasibility and agreement of remotely acquired ultrasound images for assessing components of the fetal biophysical profile. These studies suggest potential applications beyond basic fetal cardiac assessment, although such applications require further evaluation and are not included in the current U.S. FDA-authorized indications for Pulsenmore ES. Evidence supporting one clinical measurement should not automatically be extended to other diagnostic applications. Pulsenmore’s announcement of the two biophysical profile studies summarizes the results.
4. Safety and pregnancy outcomes at scale
A large retrospective cohort study in BMC Pregnancy and Childbirth compared 4,460 women using Clalit’s home ultrasound service in Israel with 102,707 non-users. The researchers found no significant differences in preterm birth or adverse neonatal outcomes between the groups.
5. Patient experience and psychological outcomes
A randomized clinical study evaluated home ultrasound among women with a history of recurrent pregnancy loss. It reported lower maternal anxiety and improved maternal-fetal attachment in the intervention group. Psychological outcomes should be interpreted in the context of the populations studied, and benefits observed among women with previous pregnancy loss cannot automatically be generalized to all pregnancies.
6. Integration into clinical practice
Successful implementation requires suitable patient selection, clinician availability, clear responsibilities for image interpretation and established pathways for follow-up when additional evaluation is needed. In the Netherlands, prospective research examined the feasibility and usability of clinician-guided home ultrasound, contributing evidence on patient experience and remote scanning workflows.
At Sheba Medical Center in Israel, researchers evaluated hybrid models combining remote monitoring with in-person maternal-fetal care. One prospective pilot involving women with gestational diabetes reported a median remote visit duration of 59 minutes, compared with 159 minutes for conventional clinic visits.
What each kind of evidence shows
| Evidence type | Key question | Examples from Pulsenmore research | What remains to be evaluated |
| Regulatory authorization | Is the technology authorized for the intended use? | FDA De Novo authorization, November 2025 | Applications beyond authorized indications |
| Clinical performance | Can patients acquire clinically useful images? | HOLA multicenter U.S. study; early feasibility studies | Performance across populations and workflows |
| Accuracy | How well do remote findings agree with conventional assessments? | Fetal heart rate validation; exploratory BPP studies | Broader diagnostic applications |
| Safety and outcomes | What happens when the technology is used in routine care? | 4,460 users compared with 102,707 controls | Prospective comparative outcomes |
| Patient experience | How does use affect patients? | Studies of anxiety, maternal-fetal attachment and usability | Long-term benefits and generalizability |
| Clinical implementation | Does it fit routine workflows and care pathways? | Netherlands prospective research; Sheba hybrid care pilot | Scalability across care settings |
Practical takeaways for decision-makers
Healthcare organizations should consider four priorities when assessing adoption.
Review the complete evidence base.
Match the evidence to the intended care model. Results obtained with clinician-guided scanning may differ from those obtained with independent app-guided scanning.
Assess implementation requirements. Review clinician capacity, image interpretation processes, patient eligibility, connectivity and pathways for in-person evaluation.
Define meaningful measures of success. In addition to technical performance, assess patient experience, access to care, clinical outcomes, operational efficiency and financial sustainability.
The broader perspective
While further research is needed to establish long-term outcomes, economic value and performance across additional populations, the available evidence provides a foundation for healthcare systems considering the integration of home ultrasound into prenatal care. The central question is no longer simply whether patients can perform ultrasound examinations at home, but how these technologies can be incorporated responsibly into clinical pathways that preserve physician-led care. Pulsenmore’s review of three years of research and real-world application summarizes this record.
Pulsenmore ES compared with Butterfly iQ3 and Philips Lumify
Butterfly iQ3 and Philips Lumify are handheld devices designed for a different care model than Pulsenmore ES. The table compares the three, because evidence should match intended use.
| Criterion | Pulsenmore ES | Butterfly iQ3 | Philips Lumify |
| Who acquires the images | Pregnant patient at home, by physician prescription | Qualified and trained healthcare professional | Healthcare professional in a clinical environment |
| Who interprets | Healthcare professionals review remotely, with physician sign-off | The professional operating the device, at the point of care | The professional operating the device, at the point of care |
| Care model | Clinician-led remote prenatal care between visits | Point-of-care imaging during a clinical encounter | Point-of-care imaging during a clinical encounter |
| Clinical scope | Fetal heart rate determination, singleton pregnancies, 14 to 38 weeks | Many body regions, including cardiac, abdominal, fetal and obstetric, and gynecological imaging | A similarly broad list of applications |
| Regulatory basis | FDA De Novo decision for prescribed home use | FDA record indicating use by qualified and trained healthcare professionals | FDA record describing use by healthcare professionals in clinical environments |
| Reported real-world use | More than 270,000 home ultrasound scans | Professional-use indications | Professional-use indications |
The sources are the FDA record for Butterfly iQ3, the FDA record for Philips Lumify and the FDA De Novo decision for Pulsenmore ES. The difference is who is authorized to operate each system and how it fits the care pathway.
FAQs
Q: What does a retrospective cohort show?
A: It shows association, not causation, and users can differ from non-users in several characteristics.
Q: What should be measured beyond technical performance?
A: Patient experience, access to care, clinical outcomes, operational efficiency and financial sustainability.
Q: What does FDA De Novo authorization mean for Pulsenmore ES?
A: It means the FDA classified Pulsenmore ES as a new type of device with no legally marketed equivalent and authorized it for marketing. The authorization covers a home-use prenatal ultrasound platform with remote physician interpretation, and a physician prescription is required. The Pulsenmore handheld ultrasound system is designed in accordance with ALARA (As Low As Reasonably Achievable) principles, which guide the use of ultrasound at the lowest levels needed to obtain clinically useful images.
Q: How accurate are scans that patients take themselves with Pulsenmore ES?
A: Accuracy depends on the measure. A validation study compared remote fetal heart rate with standard ultrasound, and in the 100-woman study, fetal heart activity was detected in 95.3 percent of scans.
Q: Has Pulsenmore ES been studied outside Israel?
A: Yes. Pulsenmore ES has been evaluated in clinical research across the U.S. and Europe. A pivotal multicenter U.S. study involving 162 women and 1,370 scans supported its FDA De Novo authorization. Additional published studies include research at Erlangen University Hospital in Germany and a prospective study in the Netherlands, while the University of Michigan investigated remote fetal biophysical profile assessments. Clinical research has also been registered in the UK, including a study at Birmingham Women’s Hospital exploring home monitoring in high-risk pregnancies.
Q: What operational evidence exists for health systems?
A: Published research from Sheba Medical Center demonstrates how home ultrasound can be integrated into hybrid prenatal care. An initial prospective study of women with gestational diabetes reported a 97.4 percent success rate for remote visits, shorter visit times (59 versus 159 minutes) and high patient satisfaction. A subsequent hospital-at-home program for high-risk pregnancies, incorporating Pulsenmore alongside other remote monitoring technologies, reported 206 admissions and nearly 3,000 days of remote care.